NUMIF logo

Numinus Wellness Inc. (NUMIF) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

NUMIF, $ (piyasa değeri 0) fiyatla Healthcare işi olan Numinus Wellness Inc.'i temsil ediyor. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 38/100 (ihtiyatlı) olarak derecelendirilmiştir.

Son analiz: 15 Mar 2026
38/100 AI Puanı

Numinus Wellness Inc. (NUMIF) Sağlık ve Boru Hattı Genel Bakışı

CEOMichael Tan
Çalışanlar200
MerkezVancouver, CA
Halka Arz Yılı2021
SektörHealthcare

Numinus Wellness Inc. provides psychedelic-assisted psychotherapy solutions, operating through its Salvation Botanicals division for laboratory services and Numinus Health for therapeutic services. The company aims to transform the mental health landscape with a focus on psychotherapy, counseling, and substance abuse treatment.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 15 Mar 2026

Yatırım Tezi

Numinus Wellness Inc. presents a speculative investment opportunity in the emerging field of psychedelic-assisted psychotherapy. Key value drivers include the expansion of its Numinus Health division and the potential for increased revenue from its Salvation Botanicals laboratory services. The company's focus on mental health and substance abuse treatment aligns with growing societal needs. However, the company's negative profit margin of -207.9% and reliance on a nascent market segment pose significant risks. The high beta of 2.56 indicates substantial volatility. Successful navigation of regulatory hurdles and demonstration of clinical efficacy are crucial for long-term growth. Investors should carefully consider the risks associated with investing in an early-stage company in a highly regulated and evolving industry.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Market capitalization of $0.01 billion indicates a micro-cap company with high growth potential but also significant risk.
  • Negative P/E ratio of -1.33 reflects current unprofitability, suggesting the company is investing heavily in growth and development.
  • Gross margin of 43.7% demonstrates the potential for profitability as the company scales its operations.
  • Profit margin of -207.9% highlights substantial losses, requiring careful monitoring of cash flow and operational efficiency.
  • Beta of 2.56 indicates high volatility compared to the market, reflecting the speculative nature of the psychedelic-assisted therapy industry.

Rakipler & Benzerleri

Güçlü Yönler

  • Specialized expertise in psychedelic-assisted psychotherapy.
  • Integrated approach combining laboratory and therapeutic services.
  • Established network of Numinus Health clinics.
  • Focus on research and development in the psychedelic space.

Zayıflıklar

  • Negative profit margin and reliance on external funding.
  • Limited operating history and small market capitalization.
  • High beta indicating significant volatility.
  • Dependence on regulatory approvals and evolving public perception.

Katalizörler

  • Ongoing: Expansion of Numinus Health clinic network to increase patient access.
  • Ongoing: Development of strategic partnerships to expand research and development capabilities.
  • Upcoming: Potential regulatory approvals for psychedelic-assisted therapies.
  • Ongoing: Increased awareness and acceptance of psychedelic-assisted therapies.
  • Ongoing: Expansion of Salvation Botanicals laboratory services to new clients.

Riskler

  • Potential: Regulatory hurdles and evolving legal landscape for psychedelic-assisted therapies.
  • Potential: Competition from other companies in the psychedelic and mental health industries.
  • Potential: Negative public perception and stigma associated with psychedelics.
  • Ongoing: Dependence on external funding and potential for dilution.
  • Ongoing: Limited operating history and small market capitalization.

Büyüme Fırsatları

  • Expansion of Numinus Health Clinics: Numinus can expand its network of Numinus Health clinics to offer psychedelic-assisted therapy and other mental health services. The market for mental health services is substantial, with a projected value of $537.96 billion in 2030. This expansion can drive revenue growth and establish Numinus as a leading provider in the space. Timeline: Ongoing.
  • Increased Utilization of Salvation Botanicals: Numinus can increase the utilization of its Salvation Botanicals division by offering comprehensive testing and research services to other companies in the psychedelic and cannabis industries. The analytical testing services market is expected to reach $13.1 billion by 2029. This can generate additional revenue streams and strengthen Numinus's position in the market. Timeline: Ongoing.
  • Strategic Partnerships and Collaborations: Numinus can pursue strategic partnerships and collaborations with research institutions, pharmaceutical companies, and other healthcare providers to advance the development and delivery of psychedelic-assisted therapies. Collaborations can accelerate research, expand market reach, and enhance Numinus's credibility. Timeline: Ongoing.
  • Development of Proprietary Psychedelic Formulations: Numinus can invest in the development of proprietary psychedelic formulations and delivery methods to differentiate itself from competitors and capture a larger share of the market. The market for psychedelic drugs is expected to grow significantly in the coming years. Developing innovative formulations can provide a competitive advantage and drive revenue growth. Timeline: Ongoing.
  • Expansion into International Markets: Numinus can expand its operations into international markets where psychedelic-assisted therapy is legal or becoming legal. The global market for mental health services is vast, and international expansion can provide significant growth opportunities. This expansion requires careful navigation of regulatory frameworks and cultural differences. Timeline: Ongoing.

Fırsatlar

  • Expansion of Numinus Health clinics and services.
  • Increased utilization of Salvation Botanicals laboratory services.
  • Strategic partnerships and collaborations with research institutions.
  • Development of proprietary psychedelic formulations and delivery methods.

Tehditler

  • Regulatory uncertainties and evolving legal landscape.
  • Competition from other companies in the psychedelic and mental health industries.
  • Potential for adverse clinical trial results.
  • Negative public perception and stigma associated with psychedelics.

Rekabet Avantajları

  • Specialized expertise in psychedelic-assisted psychotherapy.
  • Integrated approach combining laboratory services and therapeutic services.
  • Established network of Numinus Health clinics.
  • Focus on research and development in the psychedelic space.

NUMIF Hakkında

Numinus Wellness Inc., headquartered in Vancouver, Canada, is dedicated to transforming the mental health landscape through the development and delivery of psychedelic-assisted psychotherapy. The company operates through two primary divisions: Salvation Botanicals and Numinus Health. Salvation Botanicals provides laboratory services, including cultivation, analytical testing, product research and development, and ancillary services related to psychedelics. It also offers comprehensive testing services for cannabis. Numinus Health focuses on providing supportive therapies and technologies aimed at healing, connection, and personal growth, with a particular emphasis on treating mental health and substance abuse. This division offers a range of services, including psychotherapy, counseling, neurofeedback, physiotherapy, and other therapies. Furthermore, Numinus Health provides training, facilities, and operational resources to practitioners in the field. The company's holistic approach aims to integrate psychedelic-assisted therapy with traditional mental health treatments, addressing a growing need for innovative solutions in mental healthcare. Numinus Wellness Inc. is committed to advancing research and development in the psychedelic space, seeking to establish itself as a leader in this emerging field.

Ne Yaparlar

  • Provides psychedelic-assisted psychotherapy solutions.
  • Operates Salvation Botanicals division offering laboratory services.
  • Offers cultivation, analytical testing, and product research for psychedelics.
  • Provides full suite testing and custom testing of cannabis.
  • Operates Numinus Health division providing supportive therapies.
  • Offers services for psychotherapy, counseling, and neurofeedback.
  • Provides training, facilities, and operational resources to practitioners.

İş Modeli

  • Generates revenue through laboratory services provided by Salvation Botanicals.
  • Generates revenue through therapeutic services offered by Numinus Health.
  • Provides training and resources to practitioners in the mental health field.

Sektör Bağlamı

Numinus Wellness Inc. operates within the burgeoning psychedelic-assisted therapy industry, which is gaining traction as an alternative approach to mental health treatment. The market is characterized by increasing research, evolving regulatory landscapes, and growing acceptance of psychedelics for therapeutic purposes. Competitors include companies like Algernon Pharmaceuticals Inc. (ALRTF) and PharmaTher Holdings Ltd. (ANPCY), which are also exploring psychedelic-based treatments. The industry is poised for growth, driven by the rising prevalence of mental health disorders and the limitations of conventional treatments. However, regulatory uncertainties and public perception remain significant challenges.

Kilit Müşteriler

  • Individuals seeking mental health and substance abuse treatment.
  • Practitioners in the mental health field seeking training and resources.
  • Companies in the psychedelic and cannabis industries requiring laboratory services.
AI Güveni: 69% Güncellendi: 15 Mar 2026

Finansallar

Grafik & Bilgi

Numinus Wellness Inc. (NUMIF) hisse senedi fiyatı: Price data unavailable

Son Haberler

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

NUMIF için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

NUMIF için Wall Street fiyat hedefi analizi.

MoonshotScore

38/100

Bu puan ne anlama geliyor?

MoonshotScore, NUMIF'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

Yönetim: Michael Tan

CEO

Michael Tan is the CEO of Numinus Wellness Inc., overseeing the company's strategy and operations in the psychedelic-assisted psychotherapy sector. His background includes experience in managing teams and driving growth in emerging markets. He is responsible for leading the company's efforts in developing and delivering innovative mental health solutions. Tan's leadership is focused on advancing research, expanding the company's network of clinics, and building strategic partnerships to accelerate growth.

Sicil: Under Michael Tan's leadership, Numinus Wellness Inc. has focused on expanding its Numinus Health division and increasing the utilization of its Salvation Botanicals laboratory services. He has overseen the development of strategic partnerships and collaborations to advance the company's research and development efforts. Key milestones include expanding the network of clinics and navigating the evolving regulatory landscape for psychedelic-assisted therapy.

NUMIF OTC Piyasa Bilgileri

The OTC Other tier represents the lowest tier of the OTC market, indicating that Numinus Wellness Inc. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and liquidity.

  • OTC Katmanı: OTC Other
  • Açıklama Durumu: Unknown
Likidite: Liquidity for NUMIF on the OTC market is likely limited, which can result in wider bid-ask spreads and greater price volatility. Trading volume may be low, making it difficult to buy or sell large quantities of shares without significantly impacting the price. Investors should exercise caution and be aware of the potential for illiquidity when trading NUMIF on the OTC market.
OTC Risk Faktörleri:
  • Limited financial disclosure and regulatory oversight.
  • Potential for low trading volume and illiquidity.
  • Higher price volatility compared to stocks listed on major exchanges.
  • Increased risk of fraud or manipulation.
  • Dependence on external funding and potential for dilution.
Durum Tespiti Kontrol Listesi:
  • Verify the company's financial statements and SEC filings (if available).
  • Research the company's management team and their track record.
  • Assess the company's business model and competitive landscape.
  • Evaluate the company's legal and regulatory compliance.
  • Monitor the company's news and press releases for any red flags.
  • Consult with a financial advisor before investing.
  • Understand the risks associated with investing in OTC stocks.
Meşruiyet Sinyalleri:
  • Operation of physical clinic locations under the Numinus Health brand.
  • Provision of laboratory services through Salvation Botanicals.
  • Focus on research and development in the psychedelic space.
  • Presence of a management team with experience in the healthcare industry.
  • Publicly available information and press releases.

Yatırımcılar Numinus Wellness Inc. (NUMIF) Hakkında Ne Soruyor

NUMIF için değerlendirilmesi gereken temel faktörler nelerdir?

Numinus Wellness Inc. (NUMIF) şu anda yapay zeka skoru 38/100, düşük puanı gösteriyor. Temel güçlü yan: Specialized expertise in psychedelic-assisted psychotherapy.. İzlenmesi gereken birincil risk: Potential: Regulatory hurdles and evolving legal landscape for psychedelic-assisted therapies.. Bu bir finansal tavsiye değildir.

NUMIF MoonshotScore'u nedir?

NUMIF şu anda MoonshotScore'da 38/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

NUMIF verileri ne sıklıkla güncellenir?

NUMIF fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler NUMIF hakkında ne diyor?

NUMIF için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

NUMIF'a yatırım yapmanın riskleri nelerdir?

NUMIF için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Regulatory hurdles and evolving legal landscape for psychedelic-assisted therapies.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

NUMIF'ın P/E oranı nedir?

NUMIF için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için NUMIF'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

NUMIF aşırı değerli mi, yoksa düşük değerli mi?

Numinus Wellness Inc. (NUMIF)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

NUMIF'ın temettü verimi nedir?

Numinus Wellness Inc. (NUMIF) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Information is based on available data and may be subject to change.
  • OTC market data may be limited and less reliable than data from major exchanges.
Veri Kaynakları

Popüler Hisseler